欧洲医院药师协会特别兴趣小组德尔菲研究:重症监护病房用药安全改进政策建议的制定与优先级排序
用药错误是医疗系统中发病和死亡的主要原因之一,ICU患者因病情严重、治疗复杂和ICU环境挑战而更易发生用药错误。欧洲医院药师协会成立特别兴趣小组,通过文献综述和利益相关方参与制定初始政策建议,并于2022年召集由21名具备ICU和/或用药安全专业知识的医疗专业人员组成的德尔菲小组,采用改良德尔菲技术进行两轮匿名9分Likert量表优先级排序。第一轮19名参与者,多数建议达成共识,6条部分共识;第二轮18名参与者,两轮后全部32条建议达成共识。所有建议均被视为高优先级,仅1条为中优先级。作者认为这些循证政策建议可能有助于减少欧洲ICU的用药错误。
要点
- 欧洲医院药师协会特别兴趣小组通过2022年两轮改良德尔菲法,对32条ICU用药安全政策建议达成全部共识。
- 第一轮19名医疗专业人员参与,多数建议达成共识,6条为部分共识;第二轮18名参与,全部32条达成共识。
- 32条建议中31条被评为高优先级,1条被评为中优先级。
- 作者认为这些循证政策建议可能有助于减少欧洲ICU的用药错误。
适用人群与场景
- ICU患者:因病情严重、治疗复杂和ICU环境挑战而更易发生用药错误。
- 德尔菲小组成员为具备ICU和/或用药安全专业知识的医疗专业人员。
研究设计与关键结果
- 研究类型:德尔菲研究(改良德尔菲技术,两轮匿名9分Likert量表优先级排序)。
- 制定方法:基于文献综述和利益相关方参与制定初始政策建议;德尔菲小组由21名具备ICU和/或用药安全专业知识的医疗专业人员组成,于2022年召集。
- 第一轮:19名医疗专业人员参与,多数建议达成共识,6条部分共识。
- 第二轮:18名医疗专业人员参与,两轮后全部32条建议达成共识。
- 优先级:32条建议中31条为高优先级,1条为中优先级。
证据类型、等级与局限
- 证据类型:指南/共识(德尔菲研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些循证政策建议可能有助于减少欧洲ICU的用药错误。
指南或共识出处
- 欧洲医院药师协会特别兴趣小组德尔菲研究(Eur J Hosp Pharm)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Medication errors (MEs) are a leading cause of morbidity and mortality in the healthcare system. Patients admitted to intensive care units (ICUs) are potentially more susceptible to MEs due to severity of illness, the complexity of treatments they receive and the challenging nature of the ICU setting. The European Association of Hospital Pharmacists established a Special Interest Group (SIG) to undertake a programme of work to develop and prioritise recommendations to support medication safety improvement in ICUs across Europe.
METHODS: Initial policy recommendations for medication safety within the ICU environment were developed following reviews of the literature and engagement with relevant stakeholders. A Delphi panel of 21 members of the SIG, that comprised healthcare professionals (HCPs) with expertise in ICU and/or medication safety, was convened in 2022. We conducted two rounds using a modified Delphi technique whereby participants anonymously ranked on a 9-point Likert Scale the policy recommendations according to their priority for implementation.
RESULTS: In total, 32 policy recommendations were developed. In Delphi Round 1, 19 HCPs participated; consensus was achieved on most recommendations and partial consensus on six. In Delphi Round 2, 18 HCPs participated. After two Delphi rounds, consensus was achieved on all 32 recommendations. All recommendations were considered 'high priority' except one that was considered 'medium priority'.
CONCLUSIONS: Through this study it was possible to develop and prioritise evidence-based policy recommendations to enhance medication safety, which may contribute to reducing MEs in ICUs across Europe. All recommendations were considered 'high priority' for implementation except one, indicating the perceived value of these recommendations in improving medication safety through preventing MEs in ICUs.
参考来源
- Howlett M, McCarthy S, Silvari V, et al. Development and prioritisation of policy recommendations for medication safety improvement for intensive care units: a European Association of Hospital Pharmacists Special Interest Group Delphi Study. Eur J Hosp Pharm. 2025. PMID: 38604615. doi:10.1136/ejhpharm-2023-004065
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。